Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2014 Apr 28;4:4813. doi: 10.1038/srep04813

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

Xiao-fei Wang 1,2,4, Yun Feng 1,4, Ying Chen 3, Bei Li Gao 1,a, Bao-hui Han 2,b
PMCID: PMC5381218  PMID: 24770591

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is one of the reasons for the discontinuation of treatment. Olanzapine is known as an atypical antipsychotic agent, but it has been reported to be effective in treating refractory CINV due to its broad and potent inhibitory activity at multiple receptors involved in the nausea and vomiting pathways. This study was conducted to assess the efficacy of olanzapine for the prevention of CINV after moderately or highly emetogenic chemotherapy. After a search of Medline (Ovid), PubMed, CNKI, Wanfang and Weipu from 1990 to October 2013, all randomised controlled trials of olanzapine for the prevention of CINV were included in this study. The meta-analysis was performed using RevMan 5.0.19 software. 6 studies involving 726 total patients were included, of which 441 were Chinese oncology patients. We found that for both general populations and Chinese populations, antiemetic regimens including olanzapine are more effective at reducing CINV than regimens that do not include olanzapine, especially in the delayed phase of CINV.

Chemotherapy-induced nausea and vomiting (CINV) is a very common side effect of chemotherapy treatment. Failure to control nausea and vomiting may lead to a significant deterioration in quality of life1 and lead to other severe clinical conditions, such as electrolyte imbalances, dehydration, malnutrition, and non-response to treatment2. Nausea and vomiting are classified as acute (<24 h post-chemotherapy) or delayed (24–120 h post-chemotherapy) according to the time of occurrence. CINV symptoms may occur despite the optimal use of appropriate prophylaxis3. The principal neurotransmitters that drive CINV in all forms are serotonin, dopamine, acetylcholine, and substance P4. Recommendations for the prevention of CINV include 5-HT3-serotonin antagonists, glucocorticoids, substance P/neurokinin-1 antagonists, and D2-dopamine antagonists, such as phenothiazines or butyrophenones, depending upon the emetogenicity of the chemotherapy regimen and patient-specific factors. However, other subtypes of serotonin and dopamine receptors have been implicated in the pathophysiology of CINV, which may explain the phenomenon of refractory CINV despite the appropriate use of the prophylactic drugs cited above5.

The ideal antiemetic for refractory CINV is a pharmacologic agent that blocks a variety of serotonin and dopamine receptor subclasses, in addition to muscarinic and histaminergic receptors, all of which have been implicated in or theorised to contribute to CINV; such an agent should be administered once daily with few adverse reactions. Known as an atypical antipsychotic agent of the thiobenzo-diazepine class, olanzapine was approved by the USA FDA (Food and Drug Administration) for the treatment of the manifestations of psychotic disorders in 19966. Olanzapine blocks multiple neurotransmitter receptors including dopaminergic D1, D2, D3, D4 brain receptors, serotonergic 5-HT2a, 5-HT2c, 5-HT3, 5-HT6 receptors, catecholamine alpha1 adrenergic receptors, acetylcholine muscarinic receptors, and histamine H1 receptors7. Moreover, olanzapine may reduce opioid requirements in cancer patients with uncontrolled pain, cognitive impairment, or anxiety8. Due to the broad and potent inhibitory activity of olanzapine at multiple receptors involved in the nausea and vomiting pathways, this agent is an effective treatment for refractory CINV.

Results

Search results

Based on our search strategy, the primary screening produced 13 potentially relevant articles, of which 6 met the inclusion criteria as an attempt to evaluate the efficacy of olanzapine for the prevention of vomiting and nausea induced by moderately or highly emetogenic chemotherapy. (Mizukami N et al. 20139; Navari RM et al. 201110; Tan L et al.200911; X Wang et al. 201212; WK Mao et al. 201113; YL Lv et al. 201314). All articles were fully published. The detailed selection process is presented in Figure 1.

Figure 1. Flow diagram of search strategy and study selection.

Figure 1

Open in a new tab

Study characteristics

The baseline characteristics of the qualified studies are presented in Table 1. Five studies compared a regimen including olanzapine to a standard regimen. The following characteristics were found regarding the standard antiemetic regimen: 1 study used corticosteroids, a 5-HT3 receptor antagonist and a NK-1 receptor antagonist; 2 studies used corticosteroids and a 5-HT3 receptor antagonist; 1 study used only a 5-HT3 receptor antagonist; 1 study used diphenhydramine + corticosteroids + a 5-HT3 receptor antagonist; and 1 study compared olanzapine versus aprepitant for the prevention of CINV with corticosteroids and a 5-HT3 receptor antagonist. In addition, 4 studies included patients who underwent moderately to highly emetogenic chemotherapy, while 2 studies specified only highly emetogenic chemotherapy. 4 studies evaluated olanzapine's effect separately in the acute, delayed and overall phase. 1 study provided only overall data, whereas 1 study lacked overall data. All studies were blinded. All six studies defined complete response to antiemetic therapy as no vomiting and no use of rescue therapy, which allows us to conclude that it is reasonable to combine the six studies in a meta-analysis using a fixed-effects model.

Table 1. Study characteristics. (OL = Olanzapine-containing groups).

Study Ethnicity control Period OL group control group Characteristics
CR all CR all          
Mizukami N et al. 2013 Japanese Vomiting control Acute 22 22 19 22 Moderately or highly emetogenic chemotherapyC: corticosteroid + 5-HT3receptor antagonist + NK-1 receptor antagonistO: C regimen + O 5 mg/d days 0–4
Delayed 22 22 16 22        
Overall 22 22 15 22        
Navari RM et al. 2011 American Vomiting control Acute 97 121 87 120 Highly emetogenic chemotherapyC: corticosteroid + 5-HT3 receptor antagonist + NK-1 receptor antagonistO: C regimen + O 10 mg/d days 1–4
Delayed 77 121 73 120        
Overall 77 121 73 120        
Nausea control Acute 87 121 87 120      
Delayed 69 121 38 120        
Overall 69 121 38 120        
Tan L et al. 2009 Chinese Vomiting control Acute 114 121 101 108 Moderately or highly emetogenic chemotherapyC:corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days 1–5
Delayed 102 121 73 108        
Overall 102 121 63 108        
Nausea control Acute 117 121 98 108      
Delayed 93 121 50 108        
Overall 93 121 48 108        
WK Mao et al. 2011 Chinese Vomiting control Acute 45 46 38 46 Moderately or highly emetogenic chemotherapyC: corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days non unspecified
Delayed 39 46 23 46        
Overall 38 46 15 46        
X Wang et al. 2012 Chinese Vomiting control Acute 40 60 27 60 Highly emetogenic chemotherapyC: 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days 1–8
Delayed 46 60 32 60        
Nausea control Acute 46 60 42 60      
Delayed 49 60 45 60        
YL Lv et al. 2013 Chinese Vomiting control Overall 22 30 11 30 Moderately or highly emetogenic chemotherapyC: diphenhydramine + corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 5 mg/d days 1
Open in a new tab

Efficacy

In the 5 individual studies with subgroup staging data, the cumulative incidence of complete response was significantly increased in the olanzapine-containing groups on the first day of chemotherapy [Odds Ratio (OR) = 1.95, 95% confidence interval (CI) 1.17–3.23, p = 0.01, Figure 2A]. Similar results were also obtained for delayed vomiting induced by highly or moderately emetogenic chemotherapy (OR = 2.65, 95% CI 1.36–5.15, p = 0.004, Figure 2B). Overall, when the 5 studies were combined, the relative risk of a complete response was 4.07 (95% CI 1.59–10.43, Figure 2C). This combined relative risk is again significantly greater than that of standard therapy (p = 0.003), indicating that patients are more likely to experience a complete response to an olanzapine regimen than to a regimen without olanzapine.

Figure 2. Relative Risk of Complete Response.

Figure 2

Open in a new tab

Olanzapine also showed superior anti-nausea effects compared with non-olanzapine regimens in the delayed phase (OR = 2.79, 95% CI 1.76–4.43, p = 0.0001, Figure 3B) and the overall phase (OR = 3.40, 95% CI 2.31–5.00, p = 0.00001, Figure 3C). However, olanzapine did not show any superiority in the acute phase (RR = 1.34, 95% CI 0.77–2.34, p = 0.30, Figure 3A) compared with non-olanzapine regimens.

Figure 3. Relative Risk of nausea control.

Figure 3

Open in a new tab

Subgroup analyses

When only Chinese studies were included in the analysis, the overall risk of experiencing a complete response on the olanzapine regimen relative to the standard regimen ranged from 2.96 to 8.96 (OR = 5.15, p = 0.00001, Table 2). While the relative risk of a complete response was greater than non-olanzapine regimens in all 3 studies, the difference reached statistical significance only in the delayed phase (p = 0.00001) but not in the acute phase (p = 0.07). This might be due to the low incidence of emesis during the acute phase, which reduces the power of the study to demonstrate statistical significance. Regarding nausea control, we did not find that an olanzapine regimen was better than a standard regimen, in neither the acute phase nor the delayed phase (Table 2).

Table 2. Summary of the different comparative results. (OL = Olanzapine-containing groups; I2%: inconsistency index; Phet: P value for heterogeneity; OR = (CR in OL patient/CR in control group)/(non CR in OL patient/non CR in control group).

Control Period Overall or subgroup Study number (N) Participant (N) OR (95%CI) Z P I2 (%) Phet
Vomiting control Acute ALL 5 726 1.95(1.17–3.23) 2.57 0.01 19 0.29
    Chinese 3 441 2.24(0.94–5.33) 1.82 0.07 41 0.18
    All excluding different criteria 4 485 2.39(1.10–5.22) 2.19 0.03 27 0.25
  Delayed ALL 5 726 2.65(1.36–5.15) 2.88 0.004 67 0.02
    Chinese 3 441 3.11(2.00–4.83) 5.03 0.00001 0 0.42
    All excluding different criteria 4 485 3.24(2.08–5.04) 5.20 0.00001 2 0.38
  Overall ALL 5 666 4.07(1.59–10.43) 2.92 0.003 82 0.0002
    Chinese 3 381 5.15(2.96–8.96) 5.79 0.00001 21 0.28
    All excluding different criteria 4 425 5.38(3.14–9.20) 6.14 0.00001 14 0.32
Nausea control Acute ALL 3 590 1.34(0.77–2.34) 1.03 0.30 31 0.23
    Chinese 2 349 1.80(0.90–3.59) 1.67 0.10 4 0.31
    All excluding different criteria 2 349 1.80(0.90–3.59) 1.67 0.10 4 0.31
  Delayed ALL 3 590 2.79(1.76–4.43) 4.35 0.0001 38 0.20
    Chinese 2 349 2.54(1.01–6.42) 1.97 0.05 69 0.07
    All excluding different criteria 2 349 2.54(1.01–6.42) 1.97 0.05 69 0.07
  Overall ALL 2 470 3.40(2.31–5.00) 6.21 0.00001 0 0.35
Open in a new tab

When the study that compared olanzapine versus aprepitant for the prevention of CINV was excluded, no great difference was observed among the combined studies. The olanzapine regimens were more effective at preventing emesis in the acute phase (OR = 2.39, 95% CI 1.10–5.22, p = 0.03, Table 2), delayed phase (OR = 3.24, 95% CI 2.08–5.04, p = 0.00001, Table 2) and overall phase (OR = 5.38, 95% CI 3.14–9.20, p = 0.00001, Table 2). The only difference was that no statistical evidence in favour of an olanzapine regimen in nausea control was demonstrated, even in the delayed phase (OR = 2.54, 95% CI 1.01–6.42, p = 0.05, Table 2), which might be due to the smaller number of patients in these groups.

Discussion

Olanzapine was first found to be effective in the prevention and treatment of nausea in a palliative care setting and in patients with opioid-induced nausea according to some case reports15,16. A patient with leukaemia reported a significant improvement in chronic nausea with the use of olanzapine17, and in 6 patients receiving palliative care, olanzapine showed a potential use in the control of intractable nausea due to opioids, neoplasm, and/or medications18. A retrospective chart review also found that olanzapine may decrease delayed emesis in patients following moderate to highly emetogenic chemotherapy19.

Based on the clinical observations and its mechanism of action of blocking multiple neurotransmitter receptors, olanzapine is believed to be effective in the prevention and treatment of vomiting and nausea induced by chemotherapy. It can be administered once daily due to its long half-life, which would improve patient compliance. Another benefit is that it is not a cytochrome P450 inhibitor and would not interact with other drugs7.

A phase I study was designed to evaluate the maximum tolerated dose of olanzapine as an anti-emetic by utilising a 4-cohort dose escalation of 3–6 patients per cohort20. The result was 5 mg (for days −2 and −1) and 10 mg (for days 0–7).

Phase II and III studies using the dose of olanzapine in the previously described phase I trial were meta-analysed. We found that a higher rate of CR can be achieved when olanzapine was added to the standard regimen. The anti-emetic effect of Olanzapine was more significant for delayed CINV, in both the genreal populations and the Chinese populations. Several studies evaluated the anti-nausea effect of olanzapine; we also found that olanzapine-containing regimens achieved better nausea control in the delayed phase and the overall phase. Based on these data, olanzapine showed superior effects in the delayed phase, which might be due to the low incidence of emesis and nausea during the acute phase. Most of the acute cases of CINV can be addressed by doctors, as they usually occur in hospitals; therefore, delayed CINV is the patients' major concern after chemotherapy because it usually occurs at home and may result in admissions to the emergency room. Our meta-analysis showed that olanzapine is effective at controlling nausea and vomiting in the delayed phase of chemotherapy and may be considered a choice for oncologists. In addition, for patients receiving multiple-day chemotherapy or high-dose chemotherapy with stem cell transplantation, the current recommendation is to administer a first-generation 5-HT3 receptor antagonist and dexamethasone daily during each day of chemotherapy3, which appeared to be less effective at controlling delayed CINV21. Further studies may be designed to evaluate olanzapine's effect in these treatment strategies.

Many doctors may worry about the side effects of olanzapine because it was originally used as an atypical antipsychotic agent. In Navari's study10, the maximum tolerated dose of olanzapine (10 mg/d) was used, and no significant changes between the olanzapine containing regimen and the standard regimen were observed for any of the symptom scores. However, when the same dose was used in the Chinese population, Tan11 observed that 73% of patients in the test group had sleepiness during chemotherapy. Further study may be needed to determine the best dose of olanzapine for different races. The other side effects of olanzapine, such as sedation and weight gain22, may not be concerns for patients undergoing chemotherapy.

Thus, olanzapine has been shown to be a safe and effective agent for the prevention of CINV, especially in the delayed phase; it is also a highly cost-effective drug compared with 5-HT3-serotonin antagonists and NK1-antagonists. We have reasons to believe that olanzapine is a good choice for prophylactic treatment in patients receiving highly to moderately emetogenic chemotherapy. Further studies may determine not only which combinations of agents with different mechanisms will be the most beneficial for patients but also the clinical characteristics of the patient groups to achieve so called “personalised therapy”.

Methods

The Medline (Ovid), PubMed, CNKI, Wanfang, and Weipu databases were used to search for electronic publications that were published from 1990 to October, 2013. The keywords included “olanzapine” and “CINV” or “chemotherapy-induced nausea and vomiting or “nausea” or “vomiting”. If there were multiple publications from the same study group, the most complete and recent results were used. The search results were limited to articles published in English or Chinese and studies performed in humans. We did not restrict our selections based on the countries in which the studies were performed. To avoid selection bias, no study was rejected because of poor quality scores.

Ethics

The study protocol was approved by the Coordinating Ethics Committee of Ruijin Hospital, and the study methods were carried out in accordance with the approved guidelines.

Inclusion/exclusion criteria

Case control studies were included in this meta-analysis, regardless of sample size. The outcome was complete response (CR) of the acute, delayed, and overall phases of CINV after chemotherapy. CR was defined as no emetic episodes and no rescue medication. The overall phase was defined as 0–120 hours after chemotherapy.

Data extraction

Two reviewers (X.F.W. and Y.F.) independently assessed all potentially relevant studies and reached a consensus on all items. In case of disagreement, a third author provided an assessment. The following data were collected from each study: first author, year of publication, ethnicity, study design, baseline characteristics of the study population, total number of cases and controls, and emesis/nausea distribution in cases and controls. After data extraction, discrepancies were adjudicated by discussion until a consensus was reached.

Statistical methods

The meta-analysis was conducted using Review Manager software (version 5.0.19). Odds ratios (OR) and 95% confidence intervals (CI) were calculated. A heterogeneity test p > .05 was interpreted as signifying a low level of heterogeneity suitable for meta-analysis. We also performed subgroup analyses in Chinese patients.

Footnotes

The authors declare no competing financial interests.

Author Contributions Data collection: X.F.W.; statistical analysis: Y.F.; manuscript writing and editing: X.F.W., Y.C., B.L.G. and B.H.H. All of the authors have seen and approved the final version of the manuscript.

References

  1. Bloechl-Daum B., Deuson R. R., Mavros P., Hansen M. & Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 24, 4472–4478(2006). [DOI] [PubMed] [Google Scholar]
  2. Osoba D. et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer. 5, 307–333(1997). [DOI] [PubMed] [Google Scholar]
  3. Ettinger D. S. et al. Antiemesis. J Natl Compr Canc Netw. 10, 456–485(2012). [DOI] [PubMed] [Google Scholar]
  4. Hesketh P. J. Chemotherapy-induced nausea and vomiting. N Engl J Med. 358, 2482–2494(2008). [DOI] [PubMed] [Google Scholar]
  5. Herrstedt J. & Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 101, 143–150(2007). [DOI] [PubMed] [Google Scholar]
  6. Fulton B. & Goa K. L. Olanzapine: are view of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53, 281–298(1997). [DOI] [PubMed] [Google Scholar]
  7. Bymaster F. P. et al. Radioreceptor binding profile of the atypic alantipsychotic olanzapine. Neuropsychopharmacology. 14, 87–96(1996). [DOI] [PubMed] [Google Scholar]
  8. Khojainova N., Santiago-Palma J., Kornick C., Breitbart W. & Gonzales G. R. Olanzapine in the management of cancer pain. J.Pain Symptom Manage. 23, 546–550(2002). [DOI] [PubMed] [Google Scholar]
  9. Mizukami N. et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J. Pain Symptom Manage. 47, 542–550(2014). [DOI] [PubMed] [Google Scholar]
  10. Navari R. M., Gray S. E. & Kerr A. C. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 9, 188–195(2011). [DOI] [PubMed] [Google Scholar]
  11. Tan L. et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 28, 131(2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wang X. & Wang L. Effectiveness of olanzapine in prevention of chemotherapy-induced nausea and vomiting. Clin J Clinicians (Electronic Edition). 6, 7406–7407(2012). [Google Scholar]
  13. Mao W. K. & Peng L. Clinical observation of Olanzapine combined with Granisetrom and Hexadecadrol prevent nausea vomit induced by chemoradiontherapy. Chinese Journal of Medicine Guide. 13, 452–454(2011). [Google Scholar]
  14. Lu Y. L. et al. Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Clin J Cancer Prev Treat. 20, 544–554(2013). [Google Scholar]
  15. Jackson W. C. & Tavernier L. Olanzapine for intractable nausea in palliative care patients. J. Palliative Med. 6, 251–255(2003). [DOI] [PubMed] [Google Scholar]
  16. Licup N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 27, 432–434(2010). [DOI] [PubMed] [Google Scholar]
  17. Pirl W. F. & Roth A. J. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 9, 84–87(2010). [DOI] [PubMed] [Google Scholar]
  18. Jackson W. C. & Tavernier L. Olanzapine for intractable nausea in palliative care patients. J. Palliative Med. 6, 251–255 (2003). [DOI] [PubMed] [Google Scholar]
  19. Passik S. D. et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer. J. Pain Symptom Manage. 2, 526–532(2002). [DOI] [PubMed] [Google Scholar]
  20. Passik S. D. et al. A phase I trial of olanzapine for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest. 22, 383–388(2004). [DOI] [PubMed] [Google Scholar]
  21. Navari R. M. Prevention of emesis from multiple-day chemotherapy regimens. J Nat Compr Cancer Netw. 5, 51–59(2007). [DOI] [PubMed] [Google Scholar]
  22. Allison D. B. & Casey D. E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 62, 22–31(2001). [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES